Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

医学 索拉非尼 安慰剂 肝细胞癌 内科学 外科 人口 佐剂 辅助治疗 随机对照试验 癌 临床终点 癌症 病理 替代医学 环境卫生
作者
Jordi Bruix,Tadatoshi Takayama,Vincenzo Mazzaferro,Gar‐Yang Chau,Jiamei Yang,Masatoshi Kudo,Jianqiang Cai,Ronnie T. P. Poon,Kwang‐Hyub Han,Won Young Tak,Han Chu Lee,Tianqiang Song,Sasan Roayaie,Luigi Bolondi,Kwan Sik Lee,Masatoshi Makuuchi,Fabrício Henrique Pereira De Souza,Marie‐Aude Le Berre,Gerold Meinhardt,Josep Maria Llovet
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:16 (13): 1344-1354 被引量:1212
标识
DOI:10.1016/s1470-2045(15)00198-9
摘要

Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy and safety of sorafenib versus placebo as adjuvant therapy in patients with hepatocellular carcinoma after surgical resection or local ablation. Methods We undertook this phase 3, double-blind, placebo-controlled study of patients with hepatocellular carcinoma with a complete radiological response after surgical resection (n=900) or local ablation (n=214) in 202 sites (hospitals and research centres) in 28 countries. Patients were randomly assigned (1:1) to receive 400 mg oral sorafenib or placebo twice a day, for a maximum of 4 years, according to a block randomisation scheme (block size of four) using an interactive voice-response system. Patients were stratified by curative treatment, geography, Child-Pugh status, and recurrence risk. The primary outcome was recurrence-free survival assessed after database cut-off on Nov 29, 2013. We analysed efficacy in the intention-to-treat population and safety in randomly assigned patients receiving at least one study dose. The final analysis is reported. This study is registered with ClinicalTrials.gov, number NCT00692770. Findings We screened 1602 patients between Aug 15, 2008, and Nov 17, 2010, and randomly assigned 1114 patients. Of 556 patients in the sorafenib group, 553 (>99%) received the study treatment and 471 (85%) terminated treatment. Of 558 patients in the placebo group, 554 (99%) received the study treatment and 447 (80%) terminated treatment. Median duration of treatment and mean daily dose were 12·5 months (IQR 2·6–35·8) and 577 mg per day (SD 212·8) for sorafenib, compared with 22·2 months (8·1–38·8) and 778·0 mg per day (79·8) for placebo. Dose modification was reported for 497 (89%) of 559 patients in the sorafenib group and 206 (38%) of 548 patients in the placebo group. At final analysis, 464 recurrence-free survival events had occurred (270 in the placebo group and 194 in the sorafenib group). Median follow-up for recurrence-free survival was 8·5 months (IQR 2·9–19·5) in the sorafenib group and 8·4 months (2·9–19·8) in the placebo group. We noted no difference in median recurrence-free survival between the two groups (33·3 months in the sorafenib group vs 33·7 months in the placebo group; hazard ratio [HR] 0·940; 95% CI 0·780–1·134; one-sided p=0·26). The most common grade 3 or 4 adverse events were hand-foot skin reaction (154 [28%] of 559 patients in the sorafenib group vs four [<1%] of 548 patients in the placebo group) and diarrhoea (36 [6%] vs five [<1%] in the placebo group). Sorafenib-related serious adverse events included hand-foot skin reaction (ten [2%]), abnormal hepatic function (four [<1%]), and fatigue (three [<1%]). There were four (<1%) drug-related deaths in the sorafenib group and two (<1%) in the placebo group. Interpretation Our data indicate that sorafenib is not an effective intervention in the adjuvant setting for hepatocellular carcinoma following resection or ablation. Funding Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一枝清荷发布了新的文献求助10
1秒前
1秒前
yyds的应助被鱼籽派采纳,获得10
2秒前
高大的柜子完成签到 ,获得积分10
2秒前
syvshc的应助被jessie采纳,获得10
2秒前
moshang完成签到 ,获得积分10
3秒前
3秒前
xfy发布了新的文献求助200
3秒前
4秒前
5秒前
香蕉觅云的应助被Liu采纳,获得10
5秒前
huoyunli发布了新的文献求助10
5秒前
yuan完成签到,获得积分20
6秒前
彦页关注了科研通微信公众号
6秒前
含糊的剑封完成签到,获得积分10
6秒前
Sunny完成签到,获得积分10
6秒前
li完成签到 ,获得积分10
7秒前
7秒前
汉堡包的应助被顺利采纳,获得10
7秒前
兰州2026完成签到 ,获得积分10
8秒前
8秒前
yyy完成签到,获得积分10
9秒前
9秒前
9秒前
在水一方的应助被暴龙战士采纳,获得10
10秒前
10秒前
小二郎的应助被科研单身狗采纳,获得10
11秒前
11秒前
12秒前
意义发布了新的文献求助10
12秒前
王乐乐发布了新的文献求助10
13秒前
可爱的函函的应助被Sunny采纳,获得10
14秒前
bkagyin的应助被纯真的飞绿采纳,获得10
14秒前
nutrue完成签到,获得积分20
14秒前
bm023061发布了新的文献求助10
14秒前
帆帆发布了新的文献求助10
14秒前
mmmm发布了新的文献求助10
15秒前
huoyunli完成签到,获得积分10
15秒前
15秒前
Azheng发布了新的文献求助10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193514
求助须知:如何正确求助?哪些是违规求助? 9579686
关于积分的说明 21866883
捐赠科研通 7793152
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484176